Im vergangenen Jahr erzielte Sinovac Biotech Ltd für sein leistungsstärkstes Segment, Enterovirus 71 vaccines, Einnahmen von 149.22M USD. Die Region Mainland China leistete den größten Beitrag mit 261.18M USD im letzten Jahr.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Enterovirus 71 vaccines

Inactivated hepatitis vaccines

Mumps vaccines

Influenza vaccines

H5N1 vaccines

Other

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Enterovirus 71 vaccines

149.22M(60.65%)

162.54M(70.78%)

121.28M(69.57%)

35.14M(48.52%)

--(--)

Inactivated hepatitis vaccines

57.95M(23.55%)

63.43M(27.62%)

37.85M(21.71%)

20.60M(28.44%)

49.42M(73.30%)

48.45M(76.99%)

47.20M(65.76%)

39.95M(81.18%)

26.94M(47.39%)

Mumps vaccines

19.73M(8.02%)

1.66M(0.72%)

1.67M(0.96%)

477.00K(0.66%)

1.47M(2.18%)

2.15M(3.42%)

1.68M(2.34%)

--(--)

Influenza vaccines

19.14M(7.78%)

2.03M(0.88%)

13.54M(7.77%)

9.83M(13.57%)

12.67M(18.80%)

12.13M(19.28%)

12.16M(16.94%)

9.19M(18.68%)

29.90M(52.61%)

H5N1 vaccines

--(--)

6.39M(8.82%)

3.85M(5.71%)

201.00K(0.32%)

10.74M(14.96%)

--(--)

Other

--(--)

73.41K(0.15%)

--(--)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Mainland China

Foreign countries

Hong Kong

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Mainland China

261.18M(67.66%)

297.00M(82.19%)

402.96M(85.70%)

1.07B(72.94%)

10.90B(56.28%)

365.62M(71.60%)

227.11M(92.30%)

215.12M(93.67%)

172.90M(99.17%)

71.18M(98.28%)

66.78M(99.06%)

61.95M(98.45%)

70.65M(98.43%)

48.20M(97.93%)

56.41M(99.24%)

Foreign countries

124.83M(32.34%)

64.37M(17.81%)

67.21M(14.30%)

398.74M(27.06%)

8.47B(43.72%)

145.00M(28.40%)

18.94M(7.70%)

14.53M(6.33%)

1.45M(0.83%)

--(--)

Hong Kong

--(--)

1.25M(1.72%)

635.00K(0.94%)

977.00K(1.55%)

1.13M(1.57%)

1.02M(2.07%)

434.76K(0.76%)